Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05912517
Registration number
NCT05912517
Ethics application status
Date submitted
13/06/2023
Date registered
22/06/2023
Titles & IDs
Public title
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
Query!
Scientific title
A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
Query!
Secondary ID [1]
0
0
2021-002359-12
Query!
Secondary ID [2]
0
0
CR109199
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
AZALEA
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Hemolytic Disease of the Fetus and Newborn
0
0
Query!
Condition category
Condition code
Blood
0
0
0
0
Query!
Other blood disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Nipocalimab
Treatment: Drugs - Placebo
Experimental: Nipocalimab - Participants will receive nipocalimab intravenously (IV) once weekly (qw) from randomization through gestational age (GA) Week 35.
Placebo comparator: Placebo - Participants will receive matching placebo IV qw from randomization through GA Week 35.
Treatment: Drugs: Nipocalimab
Nipocalimab will be administered as an intravenous infusion.
Treatment: Drugs: Placebo
Placebo will be administered as an intravenous infusion.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Pregnancies That did not Result in Fetal Loss, Intrauterine Transfusion (IUT), Hydrops Fetalis, or Neonatal Death
Query!
Assessment method [1]
0
0
Percentage of pregnancies that did not result in fetal loss, IUT, hydrops fetalis, or neonatal death (during the neonatal period) will be reported. Hydrops fetalis is defined as the presence of greater than or equal to(\>=)2 abnormal fluid collections in the fetus or neonate, such as ascites, pleural effusions, pericardial effusion, and generalized skin edema (skin thickness greater (\>)5 millimeter (mm). PMA is the time elapsed between the first day of the last menstrual period and birth (gestational age) plus the time elapsed after birth (chronological age).
Query!
Timepoint [1]
0
0
From randomization in the study through 4 weeks of age or 41 weeks Postmenstrual Age (PMA) during neonatal period, whichever is later
Query!
Secondary outcome [1]
0
0
Number of Participants With Hemolytic Disease of the Fetus and Newborn (HDFN) by Severity
Query!
Assessment method [1]
0
0
Number of participants with HDFN by severity will be reported. The severity of HDFN is defined as: 5 (fatal): fetal or neonatal death due to any reason; 4 (severe): hydrops fetalis (in fetus or newborn) or receiving IUT during pregnancy as a result of HDFN but not 5 (fatal); 3 (moderate): neonatal exchange transfusions received as a result of HDFN related hemolysis and jaundice but not 4 (severe) or 5 (fatal); 2 (mild): neonatal simple transfusions received due to HDFN after birth, with or without phototherapy, but not 3 (moderate), 4 (severe), or 5 (fatal); and 1 (minimal or none): not in 2 (mild), 3 (moderate), 4 (severe), or 5 (fatal) as described above. Here database lock implies the last participant has given birth or terminated their pregnancy, completed the Week 4 visit after delivery, and whose neonate has also completed the Week 4 visit (or 41 weeks PMA, whichever is later) or died prior to this timepoint.
Query!
Timepoint [1]
0
0
For first database lock: from randomization in the study through 4 weeks of age or 41 weeks PMA during neonatal period, whichever is later for the first database lock; for second database lock: through 12 weeks after birth
Query!
Secondary outcome [2]
0
0
Time to First Occurrence of IUT or Hydrops Fetalis
Query!
Assessment method [2]
0
0
Time to first occurrence of IUT or hydrops fetalis will be reported.
Query!
Timepoint [2]
0
0
From randomization to delivery of baby (Up to 38 weeks)
Query!
Secondary outcome [3]
0
0
Neonatal Mortality and Morbidity Index (NMMI) in Liveborn Neonates
Query!
Assessment method [3]
0
0
The NMMI will be assessed with the following categories: fatal: fetal/neonatal death; major morbidity: any of intraventricular hemorrhage grade 3/4, seizures, hypoxic-ischemic encephalopathy, necrotizing enterocolitis stage 2/3, respiratory distress syndrome requiring mechanical ventilation, bronchopulmonary dysplasia requiring oxygen support, or persistent pulmonary hypertension; Minor morbidity: anemia requiring simple transfusion, hyperbilirubinemia requiring an exchange transfusion, hypotension requiring treatment, intraventricular hemorrhage grade 1/2, necrotizing enterocolitis stage 1, or respiratory distress syndrome not requiring mechanical ventilation; None: no major or minor morbidities described above. Hyperbilirubinemia requiring phototherapy will be classified in this category'
Query!
Timepoint [3]
0
0
Through 38 weeks PMA or at discharge if earlier than 38 weeks PMA
Query!
Secondary outcome [4]
0
0
Number of IUT's Received During the Pregnancy
Query!
Assessment method [4]
0
0
Number of IUT's received during the pregnancy will be reported.
Query!
Timepoint [4]
0
0
From randomization to delivery of baby (Up to 38 weeks)
Query!
Secondary outcome [5]
0
0
Percentage of Pregnancies With Fetal Loss
Query!
Assessment method [5]
0
0
Percentage of pregnancies with fetal loss will be reported.
Query!
Timepoint [5]
0
0
Time to delivery of baby (Up to 38 weeks)
Query!
Secondary outcome [6]
0
0
Percentage of Pregnancies With Fetal or Neonatal Death
Query!
Assessment method [6]
0
0
Percentage of pregnancies with fetal or neonatal death (through the neonatal period) as a result of HDFN will be reported.
Query!
Timepoint [6]
0
0
Through Week 4 or 41 weeks PMA
Query!
Secondary outcome [7]
0
0
Percentage of Pregnancies With Hydrops Fetalis
Query!
Assessment method [7]
0
0
Percentage of pregnancies with hydrops fetalis will be reported. Hydrops fetalis is defined as the presence of \>=2 abnormal fluid collections in the fetus or neonate, such as ascites, pleural effusions, pericardial effusion, and generalized skin edema (skin thickness \>5 mm).
Query!
Timepoint [7]
0
0
Up to 41 weeks PMA
Query!
Secondary outcome [8]
0
0
Percentage of Pregnancies Receiving IUT During Pregnancy
Query!
Assessment method [8]
0
0
Percentage of pregnancies receiving IUT during pregnancy will be reported.
Query!
Timepoint [8]
0
0
Up to 35 weeks of GA period
Query!
Secondary outcome [9]
0
0
Gestational Age (GA) at First IUT
Query!
Assessment method [9]
0
0
GA at first IUT will be reported.
Query!
Timepoint [9]
0
0
Up to 35 weeks of GA period
Query!
Secondary outcome [10]
0
0
Percentage of Pregnancies Receiving >1 IUT During Pregnancy
Query!
Assessment method [10]
0
0
Percentage of pregnancies receiving \>1 IUT during pregnancy will be reported.
Query!
Timepoint [10]
0
0
Up to 35 weeks of GA period
Query!
Secondary outcome [11]
0
0
Percentage of Pregnancies Receiving IUT or HDFN Resulting in Fetal Demise (Less Than) <GA Week 20
Query!
Assessment method [11]
0
0
Percentage of pregnancies receiving IUT or HDFN resulting in fetal demise \<GA Week 20 will be reported.
Query!
Timepoint [11]
0
0
Up to 20 weeks
Query!
Secondary outcome [12]
0
0
Gestational Age at Delivery
Query!
Assessment method [12]
0
0
Gestational age at delivery will be reported.
Query!
Timepoint [12]
0
0
Up to 38 weeks
Query!
Secondary outcome [13]
0
0
Percentage of Pregnancies With Neonatal Death Through the Neonatal Period
Query!
Assessment method [13]
0
0
Percentage of pregnancies with neonatal death through the neonatal period will be reported.
Query!
Timepoint [13]
0
0
From randomization in the study through 4 weeks of age or 41 weeks PMA during neonatal period, whichever is later
Query!
Secondary outcome [14]
0
0
Percentage of Liveborn Neonates With HDFN-related Morbidities Other Than Anemia and Hyperbilirubinemia or Jaundice
Query!
Assessment method [14]
0
0
Percentage of liveborn neonates with HDFN-related morbidities other than anemia and hyperbilirubinemia or jaundice will be reported.
Query!
Timepoint [14]
0
0
From day of birth up to 4 weeks
Query!
Secondary outcome [15]
0
0
Absolute Weight of Liveborn Neonates or Infants
Query!
Assessment method [15]
0
0
Absolute weight of liveborn neonates or infants will be reported.
Query!
Timepoint [15]
0
0
Up to 104 weeks
Query!
Secondary outcome [16]
0
0
Change From Baseline in Weight of Liveborn Neonates or Infants
Query!
Assessment method [16]
0
0
Change from baseline in weight of liveborn neonates or infants will be reported.
Query!
Timepoint [16]
0
0
Baseline to up to 104 weeks
Query!
Secondary outcome [17]
0
0
Liveborn Neonates Length of Stay in Neonatal Intensive Care Unit
Query!
Assessment method [17]
0
0
Liveborn neonates length of stay in neonatal intensive care unit will be reported.
Query!
Timepoint [17]
0
0
From day of birth up to 27 days
Query!
Secondary outcome [18]
0
0
Percentage of Liveborn Neonates Receiving Exchange Transfusions for HDFN
Query!
Assessment method [18]
0
0
Percentage of liveborn neonates receiving exchange transfusions for HDFN will be reported.
Query!
Timepoint [18]
0
0
From day of birth up to 27 days
Query!
Secondary outcome [19]
0
0
Number of Neonatal Exchange Transfusions per Liveborn Neonate
Query!
Assessment method [19]
0
0
Number of neonatal exchange transfusions per liveborn neonate will be reported.
Query!
Timepoint [19]
0
0
From day of birth up to 27 days
Query!
Secondary outcome [20]
0
0
Percentage of Liveborn Neonates or Infants with Simple Transfusions for HDFN
Query!
Assessment method [20]
0
0
Percentage of liveborn neonates or infants with simple transfusions for HDFN through the neonatal period (for the first database lock) or 12 weeks (for the second database lock) after birth will be reported.
Query!
Timepoint [20]
0
0
For first database lock: From birth up to 4 weeks; for second database lock: From birth up to 12 weeks
Query!
Secondary outcome [21]
0
0
Number of Simple Transfusions for HDFN per Liveborn Neonate or Infant
Query!
Assessment method [21]
0
0
Number of simple transfusions for HDFN per liveborn neonate or infant through the neonatal period (for the first database lock) or 12 weeks (for the second database lock) after birth will be reported.
Query!
Timepoint [21]
0
0
For first database lock: From birth up to 4 weeks; for second database lock: From birth up to 12 weeks
Query!
Secondary outcome [22]
0
0
Percentage of Liveborn Neonates With Hyperbilirubinemia Treated With Phototherapy
Query!
Assessment method [22]
0
0
Percentage of liveborn neonates with hyperbilirubinemia treated with phototherapy will be reported.
Query!
Timepoint [22]
0
0
From day of birth up to 27 days
Query!
Secondary outcome [23]
0
0
Number of Days of Phototherapy Received for Hyperbilirubinemia per Liveborn Neonate
Query!
Assessment method [23]
0
0
Number of days of phototherapy received for hyperbilirubinemia per liveborn neonate will be reported.
Query!
Timepoint [23]
0
0
From day of birth up to 27 days
Query!
Secondary outcome [24]
0
0
Percentage of Liveborn Neonates or Infants Receiving Intravenous Immunoglobulin (IVIg) for HDFN Treatment
Query!
Assessment method [24]
0
0
Percentage of liveborn neonates or infants receiving IVIg for HDFN treatment will be reported.
Query!
Timepoint [24]
0
0
For first database lock: From birth up to 4 weeks; for second database lock: From birth up to 12 weeks
Query!
Secondary outcome [25]
0
0
Number of Maternal Deaths
Query!
Assessment method [25]
0
0
Number of maternal deaths will be reported.
Query!
Timepoint [25]
0
0
Form randomization up to 24 weeks postpartum
Query!
Secondary outcome [26]
0
0
Number of Participants with Adverse Events (AEs)
Query!
Assessment method [26]
0
0
Number of participants with AEs, serious adverse events, and AEs of special interest (AESIs), AE's leading to discontinuations, infections, serious infections, infusion reactions, and hypersensitivity reactions will be reported. Treatment-emergent adverse events associated with the following situations are considered as AESIs: hypoalbuminemia, clinically significant bleeding with a corresponding placental finding on ultrasound, maternal infections that led to clinically significant morbidities or mortalities in fetus or neonates, Infections that are severe or require intravenous (IV) anti-infective or operative or invasive intervention in maternal participants or neonates or infants, and infants with hypogammaglobulinemia.
Query!
Timepoint [26]
0
0
From randomization up to 24 weeks postpartum
Query!
Secondary outcome [27]
0
0
Number of Maternal Pregnancy Complications
Query!
Assessment method [27]
0
0
Number of maternal pregnancy complications will be reported.
Query!
Timepoint [27]
0
0
Up to 38 weeks
Query!
Secondary outcome [28]
0
0
Number of IUT Related complications
Query!
Assessment method [28]
0
0
Number of participants with IUT related complications will be reported.
Query!
Timepoint [28]
0
0
Up to 35 weeks of GA period
Query!
Secondary outcome [29]
0
0
Percentage of Pregnancies With Cesarean Delivery, Preterm Birth, Fetal Growth, and Preeclampsia
Query!
Assessment method [29]
0
0
Percentage of pregnancies with cesarean delivery, cesarean delivery due to IUT complications, preterm birth \<GA week 28, preterm birth \<GA week 32, preterm birth \<GA week 34, preterm birth \<GA week 37, fetal growth restriction, and preeclampsia will be reported.
Query!
Timepoint [29]
0
0
Up to 38 weeks of GA period
Query!
Secondary outcome [30]
0
0
Percentage of Liveborn Neonates or Infants Who Died
Query!
Assessment method [30]
0
0
Percentage of liveborn neonates or infants who died will be reported.
Query!
Timepoint [30]
0
0
Up to 104 weeks
Query!
Secondary outcome [31]
0
0
Percentage of Liveborn Neonates or Infants With AEs
Query!
Assessment method [31]
0
0
Percentage of liveborn neonates or infants with AEs, SAEs, AESIs, infections, serious infections will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. Any event requiring hospitalization (or prolongation of hospitalization) that occurs during participation in the study must be reported as an SAE.
Query!
Timepoint [31]
0
0
Up to 104 weeks
Query!
Secondary outcome [32]
0
0
Percentage of Liveborn Neonates or Infants Receiving IVIg for Non-HDFN Indications
Query!
Assessment method [32]
0
0
Percentage of liveborn neonates or infants receiving IVIg for non-HDFN indications will be reported.
Query!
Timepoint [32]
0
0
Up to 104 weeks
Query!
Secondary outcome [33]
0
0
Percentage of Liveborn Neonates or Infants With Abnormal Hearing
Query!
Assessment method [33]
0
0
Percentage of liveborn neonates or infants with abnormal hearing will be reported.
Query!
Timepoint [33]
0
0
Up to 104 weeks
Query!
Secondary outcome [34]
0
0
Bayley Scales of Infant Development and Toddler Development
Query!
Assessment method [34]
0
0
The Bayley Scales of infant development is considered the standard assessment of early child development and includes cognition, language, motor skills, social emotional, and adaptive behavior will be reported. The Bayley Scales (3rd edition) are reference standards that measure infant and toddler development in five areas: cognition, language, motor skills, social-emotional and adaptive behavior. The cognition, language and motor skills scales are directly administered to the infant, while social-emotional, and adaptive behavior scales are caregiver questionnaires. The scores are standardized using norm reference samples with representative demographics and age adjusted for prematurity. Higher scores in the Bayley Scales indicate better outcomes.
Query!
Timepoint [34]
0
0
Week 52 and 104
Query!
Secondary outcome [35]
0
0
Change From Baseline in Generalized Anxiety Disorder 7-Item (GAD7) Over time During Pregnancy and Postpartum
Query!
Assessment method [35]
0
0
Change from baseline in GAD7 over time during pregnancy and postpartum will be reported. The GAD-7 scale is a self-administered questionnaire designed to measure anxiety. The recall period for all items is the past 2 weeks. Responses to all items are rated on a 4-point Likert scale ranging from 0 "not at all" to 3 "nearly every day". The total score ranges from 0 to 21, with higher scores indicating higher severity of anxiety symptoms.
Query!
Timepoint [35]
0
0
Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum
Query!
Secondary outcome [36]
0
0
Change From Baseline in Short Form 36 Version 2 (SF-36v2) Acute Form Domain Score
Query!
Assessment method [36]
0
0
Change from baseline in SF-36v2 acute form domain score will be reported. The SF-36 version 2 acute is a self-administered, 36-item questionnaire measuring health-related quality of life and includes 8 domains that measure physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality social functioning, role limitations due to emotional problems, and mental health. The 8 domains can be aggregated into 2 summary scales that reflect physical and mental health: a physical component summary and a mental component summary. Responses to all items are rated on a 3, 5, or 6-point Likert scale, with higher scores indicating better health status.
Query!
Timepoint [36]
0
0
Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum
Query!
Secondary outcome [37]
0
0
Change From Baseline in EuroQol Five-dimension Questionnaire (EQ-5D-5L) Visual Analogue Scale (VAS) Score
Query!
Assessment method [37]
0
0
Change from baseline in EQ-5D-5L visual analogue score will be reported. The EQ-5D descriptive system is comprised of 5 items across the following 5 dimensions: mobility, self-care, usual activities, pain or discomfort and anxiety or depression. The EQ-5D-5L uses a 5-point Likert response scale ranging from "no problems" to "extreme problems", with higher scores indicating better quality of life. EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ-VAS). EQ-VAS score ranges from 0 to 100, where 0 = worst imaginable health state and 100 = best imaginable health state. Higher score indicates good health state.
Query!
Timepoint [37]
0
0
Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum
Query!
Secondary outcome [38]
0
0
Change From Baseline in EuroQol 5-Dimension Descriptive (EQ-5D) Index Score
Query!
Assessment method [38]
0
0
Change from baseline in EQ-5D index score will be reported. The EQ-5D descriptive system is comprised of 5 items across the following 5 dimensions: mobility, self-care, usual activities, pain or discomfort and anxiety or depression. The EQ-5D-5L descriptive system uses a 5-point Likert response scale ranging from "no problems" to "extreme problems", with higher scores indicating better quality of life.
Query!
Timepoint [38]
0
0
Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum
Query!
Secondary outcome [39]
0
0
Infant Health-Related Quality of Life Instrument (IQI) Score for Neonate or Infant Overtime
Query!
Assessment method [39]
0
0
IQI score for neonate or infant will be reported. The IQI consists of 7 health attributes including sleeping, feeding, breathing, stooling or poo, mood, skin, and interaction. Responses to all items are rated on a 4-point Likert scale, with higher scores indicating better quality of life.
Query!
Timepoint [39]
0
0
Weeks 4, 8 and 52
Query!
Eligibility
Key inclusion criteria
* Pregnant and an estimated gestational age (GA) (based on ultrasound dating) from Week 13^0/7 to Week 16^6/7 at randomization
* History of severe Hemolytic Disease of the Fetus and Newborn (HDFN) in a prior pregnancy defined as:
1. documented fetal anemia, or received greater than or equal to (>=)1 IUT as a result of HDFN or
2. fetal loss or neonatal death as a result of HDFN, with maternal alloantibody titers for Rhesus antigen D protein (RhD), Kell, Kell Rhesus antigen C protein (Rhc), Rhesus antigen E protein (RhE), or RhC antigen above the critical levels (anti-Kell >=4; other >=16) and evidence of an antigen-positive fetus
* During the current pregnancy, presence of maternal alloantibody to RhD, Rhc, RhE, or RhC antigen with titers above the critical level (anti-Kell >= 4; other >=16) based on the designated central lab results at screening
* Evidence of antigen-positivity corresponding to the current maternal alloantibody (RhD, Kell, Rhc, RhE, or RhC) confirmed by non-invasive antigen cell-free fetal DNA (cffDNA) performed at the central laboratory.
* Have screening laboratory values within the study protocol-specified parameters: a) albumin, >=2.6 grams (g) per deciliter (g/dL), international system (SI): >=26 gram per liter (g/L); b) alanine transaminase (AST) less than or equal to (<=) 2 × upper limit of normal (ULN); c) alanine transaminase (ALT) <=2 × ULN d) creatinine <=0.8 milligrams per deciliter (mg/dL), SI: <=70.7 micromole per liter (µmol/L), and Serum total immunoglobulins G (IgG) = 600 mg/dL SI: >=6 g/L
* Otherwise healthy on the basis of physical examination, medical history, vital signs, 12-lead ECG, and clinical laboratory tests performed at screening.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
45
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Currently pregnant with a multiple gestation (twins or more)
* Evidence of fetal anemia prior to randomization in the current pregnancy
* Current uncontrolled hypertension
* History of myocardial infarction, unstable ischemic heart disease, or stroke
* Has any confirmed or suspected clinical immunodeficiency syndrome or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant
* Has inflammatory or autoimmune diseases requiring immunosuppressive therapies that may jeopardize the safety of the participant
* Currently has a malignancy or has a history of malignancy within 3 years before screening (with the exception of localized basal cell carcinoma and/or squamous cell carcinoma skin cancer that has been adequately treated with no evidence of recurrence for at least 3 months
* Is currently receiving systemic corticosteroids or other immunosuppressants for disorders unrelated to the pregnancy
* Has received or planning to receive plasmapheresis, immunoadsorption therapy, intravenous immunoglobulin (IVIg), or any immunoglobulin (Ig)G fragment crystallizable (Fc)-related protein therapeutics during the current pregnancy
* Has a severe infection including opportunistic infections
* Presence of abnormal (protocol-specified) hematologic laboratory values during screening
* History of severe preeclampsia prior to GA Week 34 or severe fetal growth restriction (estimated fetal weight <3rd percentile, based on local fetal growth normative standards) in a previous pregnancy
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
20/12/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
10/07/2029
Query!
Actual
Query!
Sample size
Target
120
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Mater Hospital Brisbane - South Brisbane
Query!
Recruitment hospital [2]
0
0
Liverpool Hospital - Sydney
Query!
Recruitment postcode(s) [1]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [2]
0
0
2170 - Sydney
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Illinois
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
North Carolina
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Texas
Query!
Country [4]
0
0
Argentina
Query!
State/province [4]
0
0
Buenos Aires
Query!
Country [5]
0
0
Argentina
Query!
State/province [5]
0
0
Ciudad Autonoma Buenos Aires
Query!
Country [6]
0
0
Belgium
Query!
State/province [6]
0
0
Bruxelles
Query!
Country [7]
0
0
Belgium
Query!
State/province [7]
0
0
Leuven
Query!
Country [8]
0
0
Brazil
Query!
State/province [8]
0
0
Belo Horizonte
Query!
Country [9]
0
0
Brazil
Query!
State/province [9]
0
0
Goiania
Query!
Country [10]
0
0
Brazil
Query!
State/province [10]
0
0
Recife
Query!
Country [11]
0
0
Brazil
Query!
State/province [11]
0
0
Rio de Janeiro
Query!
Country [12]
0
0
Brazil
Query!
State/province [12]
0
0
Sao Paulo
Query!
Country [13]
0
0
Germany
Query!
State/province [13]
0
0
Giessen
Query!
Country [14]
0
0
Israel
Query!
State/province [14]
0
0
Petah Tikva
Query!
Country [15]
0
0
Israel
Query!
State/province [15]
0
0
Ramat Gan
Query!
Country [16]
0
0
Japan
Query!
State/province [16]
0
0
Fukuoka
Query!
Country [17]
0
0
Japan
Query!
State/province [17]
0
0
Gifu
Query!
Country [18]
0
0
Japan
Query!
State/province [18]
0
0
Sendai
Query!
Country [19]
0
0
Netherlands
Query!
State/province [19]
0
0
Leiden
Query!
Country [20]
0
0
Spain
Query!
State/province [20]
0
0
Barcelona
Query!
Country [21]
0
0
Spain
Query!
State/province [21]
0
0
Madrid
Query!
Country [22]
0
0
Spain
Query!
State/province [22]
0
0
Sevilla
Query!
Country [23]
0
0
United Kingdom
Query!
State/province [23]
0
0
Birmingham
Query!
Country [24]
0
0
United Kingdom
Query!
State/province [24]
0
0
Manchester
Query!
Country [25]
0
0
United Kingdom
Query!
State/province [25]
0
0
Oxford
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Janssen Research & Development, LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to assess the effectiveness of nipocalimab when compared to placebo in decreasing the risk of fetal anemia (a condition in which a baby's red blood cell volume falls below normal levels while the baby is developing in the womb) with live neonates in pregnant participants at risk for severe hemolytic disease of the fetus and newborn.
Query!
Trial website
https://clinicaltrials.gov/study/NCT05912517
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Janssen Research & Development, LLC Clinical Trial
Query!
Address
0
0
Janssen Research & Development, LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Study Contact
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
844-434-4210
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Query!
When will data be available (start and end dates)?
Query!
Available to whom?
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://www.janssen.com/clinical-trials/transparency
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT05912517